Synergistic Anticancer Effects of Gemcitabine with Pitavastatin on Pancreatic Cancer Cell Line MIA PaCa-2 in vitro and in vivo

References

• Rahib L, Smith BD, Aizenberg R, et al. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the united states. Cancer Res. 2014;74:2913–2921. doi:10.1158/0008-5472.CAN-14-015524840647
   PubMed Web of Science ®Google Scholar
• SEER Cancer Stat Facts: Pancreatic Cancer. Bethesda: National Cancer Institute; 4 2019 Available from: https://seer.cancer.gov/statfacts/html/pancreas.html. Accessed 520, 2020.
   Google Scholar
• Kamisawa T, Isawa T, Koike M, et al. Hematogenous metastases of pancreatic ductal carcinoma. Pancreas. 1995;11:345–349. doi:10.1097/00006676-199511000-000058532650
   PubMed Web of Science ®Google Scholar
• Labori KJ, Katz MH, Tzeng CW, et al. Impact of early disease progression and surgical complications on adjuvant chemotherapy completion rates and survival in patients undergoing the surgery first approach for resectable pancreatic ductal adenocarcinoma—a population-based cohort study. Acta Oncol. 2016;55:265–277. doi:10.3109/0284186X.2015.106844526213211
   PubMed Web of Science ®Google Scholar
• Neoptolemos JP, Palmer DH, Ghaneh P, et al. European Study Group for Pancreatic Cancer. Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, Phase 3 trial. Lancet. 2017;389:1011–1024.28129987
   PubMed Web of Science ®Google Scholar
• Golcher H, Brunner TB, Witzigmann H, et al. Neoadjuvant chemoradiation therapy with gemcitabine/cisplatin and surgery versus immediate surgery in resectable pancreatic cancer: results of the first prospective randomized Phase II trial. Strahlenther Onkol. 2015;191:7–16. doi:10.1007/s00066-014-0737-725252602
   PubMed Web of Science ®Google Scholar
• Regine WF, Winter KA, Abrams RA, et al. Fluorouracil vs gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma: a randomized controlled trial. JAMA. 2008;299:1019–1026. doi:10.1001/jama.299.9.101918319412
   PubMed Web of Science ®Google Scholar
• Sandler AB, Nemunaitis J, Denham C, et al. Phase III trial of gemcitabine plus cisplatin vs. cisplatin alone in patients with locally advanced or metastatic non-small cell lung cancer. J Clin Oncol. 2000;18:122–130.10623702
   PubMed Web of Science ®Google Scholar
• von der Maase H, Hansen SW, Roberts JT, et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol. 2000;18:3068–3070. doi:10.1200/JCO.2000.18.17.306811001674
   PubMed Web of Science ®Google Scholar
• Albain KS, Nag SM, Calderillo-Ruiz G, et al. Global phase III study of gemcitabine plus paclitaxel (GT) vs. paclitaxel (T) as frontline therapy for metastatic breast cancer (MBC): first report of overall survival. J Clin Oncol. 2004;22(suppl 14):510. doi:10.1200/jco.2004.22.14_suppl.510
   Google Scholar
• Burris HA, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol. 1997;15:2403–2413. doi:10.1200/JCO.1997.15.6.24039196156
   PubMed Web of Science ®Google Scholar
• Kim MP, Gallick GE. Gemcitabine resistance in pancreatic cancer: picking the key players. Clin Cancer Res. 2008;14:1284–1285. doi:10.1158/1078-0432.CCR-07-224718316544
   PubMed Web of Science ®Google Scholar
• de Sousa Cavalcante L, Monteiro G. Gemcitabine: metabolism and molecular mechanisms of action, sensitivity and chemoresistance in pancreatic cancer. Eur J Pharmacol. 2014;741:8–16. doi:10.1016/j.ejphar.2014.07.04125084222
   PubMed Web of Science ®Google Scholar
• Amrutkar M, Gladhaug IP. Pancreatic cancer chemoresistance to gemcitabine. Cancers. 2017;9:E157. doi:10.3390/cancers911015729144412
   PubMed Web of Science ®Google Scholar
• Jakobisiak M, Golab J. Potential antitumor effects of statins (Review). Int J Oncol. 2003;23:1055–1069.12963986
   PubMed Web of Science ®Google Scholar
• Altwairgi AK. Statins are potential anticancerous agents (Review). Oncol Rep. 2015;33:1019–1039. doi:10.3892/or.2015.374125607255
   PubMed Web of Science ®Google Scholar
• Kubatka P, Bojková B, Kassayová M, et al. Combination of pitavastatin and melatonin shows partial antineoplastic effects in a rat breast carcinoma model. Acta Histochem. 2014;116:1454–1461. doi:10.1016/j.acthis.2014.09.01025450902
   PubMed Web of Science ®Google Scholar
• You HY, Zhang WJ, Xie XM, et al. Pitavastatin suppressed liver cancer cells in vitro and in vivo. Onco Targets Ther. 2016;9:5383–5388. doi:10.2147/OTT.S10690627621652
   PubMed Web of Science ®Google Scholar
• de Wolf E, Abdullah MI, Jones SM, et al. Dietary geranylgeraniol can limit the activity of pitavastatin as a potential treatment for drug-resistant ovarian cancer. Sci Rep. 2017;7:5410. doi:10.1038/s41598-017-05595-428710496
   PubMed Web of Science ®Google Scholar
• Abdullah MI, Abed MN, Richardson A. Inhibition of the mevalonate pathway augments the activity of pitavastatin against ovarian cancer cells. Sci Rep. 2017;7(1):8090.28808351
   PubMedGoogle Scholar
• Al-Qatati A, Aliwaini S. Combined pitavastatin and dacarbazine treatment activates apoptosis and autophagy resulting in synergistic cytotoxicity in melanoma cells. Oncol Lett. 2017;14:7993–7999. doi:10.3892/ol.2017.718929344241
   PubMed Web of Science ®Google Scholar
• Paškevičiūtė M, Petrikaitė V. Differences of statin activity in 2D and 3D pancreatic cancer cell cultures. Drug Des Devel Ther. 2017;11:3273–3280. doi:10.2147/DDDT.S149411
   PubMed Web of Science ®Google Scholar
• Ouyang G, Liu Z, Huang S, et al. Gemcitabine plus cisplatin versus gemcitabine alone in the treatment of pancreatic cancer: a meta-analysis. World J Surg Oncol. 2016;14:59. doi:10.1186/s12957-016-0813-926927942
   PubMed Web of Science ®Google Scholar
• Neoptolemos JP, Palmer DH, Ghaneh P, et al. Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial. Lancet. 2017;389(10073):1011–1024.28129987
   PubMed Web of Science ®Google Scholar
• Yunis AA, Arimura GK, Russin DJ. Human pancreatic carcinoma (MIA PaCa-2) in continuous culture: sensitivity to asparaginase. Int J Cancer. 1977;19:128–135. doi:10.1002/ijc.2910190118832918
   PubMed Web of Science ®Google Scholar
• Chou T-C, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enz Regul. 1984;22:27–55. doi:10.1016/0065-2571(84)90007-4
   PubMedGoogle Scholar
• Le N, Vinci A, Schober M, et al. Real-world clinical practice of intensified chemotherapies for metastatic pancreatic cancer: results from a pan-european questionnaire study. Digestion. 2016;94:222–229. doi:10.1159/00045325728030863
   PubMed Web of Science ®Google Scholar
• Zhong S, Qie S, Yang L, et al. S-1 monotherapy versus S-1 combination therapy in gemcitabine-refractory advanced pancreatic cancer: a meta-analysis (PRISMA) of randomized control trials. Medicine (Baltimore). 2017;96:e7611. doi:10.1097/MD.000000000000761128746215
   PubMed Web of Science ®Google Scholar
• Neoptolemos JP, Palmer DH, Ghaneh P, et al. European Study Group for Pancreatic Cancer. Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial. Lancet. 2017;389(10073):1011–1024.28129987
   PubMed Web of Science ®Google Scholar
• Huang P, Chubb S, Hertel LW, et al. Action of 2ʹ,2ʹ- difluorodeoxycytidine on DNA synthesis. Cancer Res. 1991;51:6110–6117.1718594
   PubMed Web of Science ®Google Scholar
• Ferreira CG, Span SW, Peters GJ, et al. Chemotherapy triggers apoptosis in a caspase-8-dependent and mitochondria-controlled manner in the non-small cell lung cancer cell line NCI-H460. Cancer Res. 2000;60:7133–7141.11156422
   PubMed Web of Science ®Google Scholar
• Chandler NM, Canete JJ, Callery MP. Caspase-3 drives apoptosis in pancreatic cancer cells after treatment with gemcitabine. J Gastrointest Surg. 2004;8:1072–1078. doi:10.1016/j.gassur.2004.09.05415585396
   PubMed Web of Science ®Google Scholar
• Fujino M, Miura S, Matsuo Y, et al. Pitavastatin-induced downregulation of CCR2 and CCR5 in monocytes is associated with the arrest of cell-cycle in S phase. Atherosclerosis. 2006;187:301–308. doi:10.1016/j.atherosclerosis.2005.10.00816289073
   PubMed Web of Science ®Google Scholar
• Jiang P, Mukthavaram R, Chao Y, et al. In vitro and in vivo anticancer effects of mevalonate pathway modulation on human cancer cells. Br J Cancer. 2014;111:1562–1571. doi:10.1038/bjc.2014.43125093497
   PubMed Web of Science ®Google Scholar
• Gbelcová H, Rimpelová S, Knejzlík Z, et al. Isoprenoids responsible for protein prenylation modulate the biological effects of statins on pancreatic cancer cells. Lipids Health Dis. 2017;16:250. doi:10.1186/s12944-017-0641-029262834
   PubMed Web of Science ®Google Scholar
• Bocci G, Fioravanti A, Orlandi P, et al. Fluvastatin synergistically enhances the antiproliferative effect of gemcitabine in human pancreatic cancer MIAPaCa-2 cells. Br J Cancer. 2005;93:319–330. doi:10.1038/sj.bjc.660272016052215
   PubMed Web of Science ®Google Scholar
• Tsuboi Y, Kurimoto M, Nagai S, et al. Induction of autophagic cell death and radiosensitization by the pharmacological inhibition of nuclear factor-kappa B activation in human glioma cell lines. J Neurosurg. 2009;110:594–604. doi:10.3171/2008.8.JNS1764819046042
   PubMed Web of Science ®Google Scholar
• Blanquicett C, Saif MW, Buchsbaum DJ, et al. Antitumor efficacy of capecitabine and celecoxib in irradiated and lead-shielded, contralateral human BxPC-3 pancreatic cancer xenografts: clinical implications of abscopal effects. Clin Cancer Res. 2005;11:8773–8781. doi:10.1158/1078-0432.CCR-05-062716361565
   PubMed Web of Science ®Google Scholar
• Byeon HJ, Choi SH, Choi JS, et al. Apoptotic activity and antitumor efficacy of PEGylated TNF-related apoptosis-inducing ligand (TRAIL) in a Mia Paca-2 cell-xenografted mouse model. Biomed Pharmacother. 2014;68:65–69. doi:10.1016/j.biopha.2013.10.01024268811
   PubMed Web of Science ®Google Scholar
• Smith PF, Grossman SJ, Gerson RJ, et al. Studies on the mechanism of simvastatin- induced thyroid hypertrophy and follicular cell adenoma in the rat. Toxicol Pathol. 1991;19:197–205. doi:10.1177/0192623391019003011780636
   PubMed Web of Science ®Google Scholar
• Robison RL, Suter W, Cox RH. Carcinogenicity and mutagenicity studies with fluvastatin, a new, entirely synthetic HMG CoA reductase inhibitor. Fundam Appl Toxicol. 1994;23:9–20. doi:10.1006/faat.1994.10737958569
   PubMedGoogle Scholar
• Lamprecht J, Wojcik C, Jakobisiak M, et al. Lovastatin induces mitotic abnormalities in various cell lines. Cell Biol Int. 1999;23(1):51–60. doi:10.1006/cbir.1998.032210527548
   PubMed Web of Science ®Google Scholar
• Warburg O. On respiratory impairment in cancer cells. Science. 1956;124(3215):269–270.13351639
   PubMed Web of Science ®Google Scholar
• Sastre-Serra J, Valle A, Company MM, et al. Estrogen down- regulates uncoupling proteins and increases oxidative stress in breast cancer. Free Radic Biol Med. 2010;48:506–512. doi:10.1016/j.freeradbiomed.2009.11.02519969066
   PubMed Web of Science ®Google Scholar
• Solaini G, Sgarbi G, Baracca A. Oxidative phosphorylation in cancer cells. Biochim Biophys Acta. 2011;1807:534–542. doi:10.1016/j.bbabio.2010.09.00320849810
   PubMed Web of Science ®Google Scholar
• Houston MA, Augenlicht LH, Heerdt BG. Intrinsic mitochondrial membrane potential and associated tumor phenotype are independent of MUC1 over-expression. PLoS One. 2011;6:e25207. doi:10.1371/journal.pone.002520721966455
   PubMedGoogle Scholar
• Zhu YY, Huang HY, Wu YL. Anticancer and apoptotic activities of oleanolic acid are mediated through cell cycle arrest and disruption of mitochondrial membrane potential in HepG2 human hepatocellular carcinoma cells. Mol Med Rep. 2015;12:5012–5018. doi:10.3892/mmr.2015.403326151733
   PubMed Web of Science ®Google Scholar
• Dey R, Moraes CT. Lack of oxidative phosphorylation and low mitochondrial membrane potential decrease susceptibility to apoptosis and do not modulate the protective effect of Bcl-x(L) in osteosarcoma cells. J Biol Chem. 2000;275:7087–7094. doi:10.1074/jbc.275.10.708710702275
   PubMed Web of Science ®Google Scholar
• Vander Heiden MG, Chandel NS, Williamson EK, et al. Bcl-xL regulates the membrane potential and volume homeostasis of mitochondria. Cell. 1997;91:627–637. doi:10.1016/S0092-8674(00)80450-X9393856
   PubMed Web of Science ®Google Scholar
• Yue W, Lee JK, Abe K, et al. Decreased hepatic breast cancer resistance protein expression and function in multidrug resistance-associated protein 2-deficient TR− rats. Drug Metab Dispos. 2011;39:441–447. doi:10.1124/dmd.110.03518821106720
   PubMed Web of Science ®Google Scholar